The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database

March 25, 2020Posted inDrug Safety Studies, Safety of new therapies for autoimmune disorders, Select Publications
Journal: Journal of the American Academy of Dermatology Authors: Rebecca Persson, Katrina Wilcox Hagberg, Yiran Qian, Catherine Vasilakis-Scaramozza, Susan Jick NLM Citation: Persson R, Hagberg KW, Qian Y, Vasilakis-Scaramozza C, Jick S. The risk…

The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database

February 28, 2020Posted inDrug Safety Studies, Safety of new therapies for autoimmune disorders, Select Publications
Journal: Journal of the European Academy of Dermatology and Venereology Authors: C Vasilakis-Scaramozza, R Persson, K W Hagberg, S Jick NLM Citation: Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S. The risk of…

Herpes zoster, hepatitis C, and tuberculosis risk with apremilast compared to biologics, DMARDs and corticosteroids to treat psoriasis and psoriatic arthritis

February 12, 2020Posted inDrug Safety Studies, Safety of new therapies for autoimmune disorders, Select Publications
Journal: Clinical Epidemiology Authors: Katrina Wilcox Hagberg, Rebecca Persson, Catherine Vasilakis-Scaramozza, Steve Niemcryk, Michael Peng, Maria Paris, Anders Lindholm, Susan Jick NLM Citation: Hagberg KW, Persson R, Vasilakis-Scaramozza C, Niemcryk S, Peng M, Paris M, Lindholm A,…